Targeted Delivery of Crispr/Cas13 As a Promising Therapeutic Approach to Treat Sars-Cov-2 Publisher Pubmed



Abbaszadehgoudarzi K¹ ; Nematollahi MH^{2, 6} ; Khanbabaei H³ ; Nave HH⁴ ; Mirzaei HR⁵ ; Pourghadamyari H^{2, 6} ; Sahebkar A^{7, 8, 9, 10} Show Affiliations
Source: Current Pharmaceutical Biotechnology Published:2021

Abstract

On a worldwide scale, the outbreak of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has led to extensive damage to the health system as well as the global economy. Hitherto, there has been no approved drug or vaccine for this disease. Therefore, the use of general antiviral drugs is at the first line of treatment, though complicated with limited effectiveness and systemic side effects. Given the pathophysiology of the disease, researchers have proposed various strategies not only to find a more specific therapeutic way but also to reduce the side effects. One strategy to accom-plish these goals is to use CRISPR/Cas13 system. Recently, a group of scientists has used the CRISPR/Cas13 system, which is highly effective in eliminating the genome of RNA viruses. Due to the RNA nature of the coronavirus genome, it seems that this system can be effective against the dis-ease. The main challenge regarding the application of this system is to deliver it to the target cells effi-ciently. To solve this challenge, it seems that using virosomes with protein S on their membrane surface can be helpful. Studies have shown that protein S interacts with its specific receptor in target cells named Angiotensin-Converting Enzyme 2 (ACE2). Here, we propose if CRISPR/Cas13 gene constructs reach the infected cells efficiently using a virosomal delivery system, the virus genome will be cleaved and inactivated. Considering the pathophysiology of the disease, an important step to imple-ment this hypothesis is to embed protein S on the membrane surface of virosomes to facilitate the delivery of gene constructs to the target cells. © 2021 Bentham Science Publishers.